STAT3 Inhibitor Compounds with Pyrimidine Scaffold

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for improved cancer therapeutics and methods of treatment, particularly targeting STAT3, which is involved in various cancers and autoimmune diseases.

Innovation Solution

The development of compounds with specific formulas, such as (A-1), (I), (Ia), (Ib), (II), (III), (IV), and (V), which act as inhibitors of STAT3, potentially offering therapeutic benefits in cancer and other diseases mediated by STAT3 activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing cancer therapeutics are used, then treatment options are limited, but therapeutic efficacy is insufficient for STAT3-mediated diseases

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidtreatment options

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent employs parameter changes by developing a series of chemically modified compounds with varying substituents (R1, R1a, R2, R3, R4, R5, R6, R7, Ra, Rb) and structural parameters (α, p) to optimize STAT3 inhibition efficacy. The core structure features systematic variations in molecular parameters including halogen substitutions, alkyl groups, and heteroaryl moieties to enhance therapeutic effectiveness against STAT3-mediated cancers while maintaining selectivity

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention creates composite molecular structures combining a core pyrimidine or pyridine ring system with diverse aromatic substituents (Ring A, Ring B) and linker groups (L, Za, Zb). This composite approach integrates multiple functional moieties into single molecules that simultaneously achieve high STAT3 binding affinity and improved pharmacological properties, expanding treatment options for STAT3-driven diseases

Inventive Principle:

Principle #40Composite materials

2Reliability

If STAT3 inhibition is achieved, then cancer treatment efficacy improves, but compound complexity increases

Engineering Contradiction:

ImproveSTAT3 inhibition efficacyVSAvoidcompound structure complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent segments the inhibitor molecule into distinct functional domains: a core heterocyclic scaffold (pyrimidine/pyridine), aromatic substituent rings (Ring A, Ring B with defined heteroatom compositions), linker regions (L, Za, Zb), and terminal functional groups (R1-R7, Ra, Rb). This segmentation allows systematic optimization of each domain's contribution to STAT3 binding while managing overall molecular complexity through modular design

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The core heterocyclic structure serves multiple functions simultaneously: it provides the primary STAT3 binding interface, establishes optimal spatial orientation for inhibitor-enzyme interaction, and offers a platform for attaching diverse substituents that fine-tune pharmacological properties. This multi-functionality reduces the need for overly complex structures by making the core scaffold highly versatile

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20250059161A1Compounds and methods for modulating STAT3

Publication Date: 2025.02.20 VIVIDION THERAPEUTICS INC

AI summary

Compounds and methods for inhibiting STAT3.